好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

WeB: A Pilot Study of WEarables for Bladder Monitoring in People with Multiple Sclerosis
Multiple Sclerosis
S7 - Multiple Sclerosis: Special Populations and Non-MS CNS Neuroinflammatory Disease (5:06 PM-5:18 PM)
009

Report findings from a pilot study of bladder wearables in people with multiple sclerosis (PwMS)

Bladder dysfunction (BD) affects many PwMS and other neurological conditions. Sequelae include inherent bother, life-threatening infections, and decreased quality of life. Remote monitoring of BD through wearables could reduce substantial existing accessibility barriers to monitoring BD progression and instituting timely treatment.

Phase I, a “Wearables for the Bladder” kit was selected by stakeholders using a human-centered design. The highest scoring tool for initial evaluation was DFree (a small non-invasive ultrasound patch measuring bladder urine volume). Phase II (feasibility study), women with MS (progressive or relapsing) and BD were enrolled (target N=20). Activities included a clinical post-void residual (PVR), wearing DFree for at least 3-5 days/month over 12-weeks, and a 3-day bladder diary. From raw minute-level device data, two measures were generated: home PVR (dPVR) and urinary frequency (dFrequency). Participant qualitative feedback on daily use was captured.

Among 21 participants enrolled (13 completers, 6 on-study, 2 dropouts), mean age was 50 (SD8.0), median EDSS was 4.0. Device utilization was on-target: mean use was 14.1 days.  Bland-Altman agreement was good between PVR and dPVR, with no systematic bias. Similar agreement was noted using all available dPVR data vs. just first 7 days; but d-PVR further visualized day-to-day variability not appreciated using single clinic snapshots. The correlation between dFrequency (mean 7.4, SD 2.9) and diary-reported frequency was 0.81. Participant feedback showed excellent usability, usefulness and ease of use and highlighted utility of DFree data for BD self-management: planning activities outside the home, reducing leakage frequency, and motivating to seek further treatment.

This pilot study provides initial insights into feasibility, validity and clinical utility of wearables to assess, monitor and treat BD. Knowledge gained includes optimization of device usage, data cleaning into novel outcomes, and targets for behavioral change.

Authors/Disclosures
Valerie A. Block, DPTSc (University of California, San Francisco)
PRESENTER
The institution of Dr. Block has received research support from National MS Society.
Anne Suskind No disclosure on file
Chu-Yueh Guo, MD (UCSF Medical Center) Dr. Guo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG therapeutics.
Shane Poole (UCSF) Shane Poole has nothing to disclose.
Gary R. Cutter, PhD (University of Alabama At Birmingham) Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.
Riley Bove, MD, FAAN (University of California, San Francisco) Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme-Sanofi. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD-Serono. Dr. Bove has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cadenza. The institution of Dr. Bove has received research support from Biogen. The institution of Dr. Bove has received research support from Eli Lilly. The institution of Dr. Bove has received research support from Novartis. The institution of Dr. Bove has received research support from Roche Genentech.